04/21/2014 - 11:40

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered a molecule, or biomarker, called CD61 on the surface of drug-resistant tumors that appears responsible for inducing tumor metastasis by enhancing the stem cell-like properties of cancer cells.

04/04/2014 - 08:48

A team led by a scientist from the Florida campus of The Scripps Research Institute (TSRI) has identified a new biomarker linked to better outcomes of patients with head and neck cancers and non-small cell lung cancer. The work could help scientists develop new diagnostics and therapies and help physicians determine the best long-term treatments for patients with these cancers.


03/13/2014 - 08:24

Only one third of individuals identified as being at clinical high risk for psychosis actually convert to a psychotic disorder within a 3 year follow-up period. This risk assessment is based on the presence of sub-threshold psychotic-like symptoms.


02/20/2014 - 12:08

Care of premature infants has improved, however they remain vulnerable to infections including a bowel infection called necrotizing enterocolitis (NEC). A new study from Loyola University published in the Journal of Pediatric Surgery has identified low reticulated platelets as a potential biomarker for early detection of this life-threatening disease.


09/19/2013 - 15:55

Mayo Clinic researchers have shown that a specific protein pair may be a successful prognostic biomarker for identifying smoking-related lung cancers. The protein — ASCL1 — is associated with increased expression of the RET oncogene, a particular cancer-causing gene called RET. The findings appear in the online issue of the journal Oncogene.


07/01/2013 - 13:51

UNC scientists used GEMMs to develop biomarkers for challenging molecular subtypes of human breast cancer, those for which there are fewer targets and therapies.  Their work helps to further establish genetically engineered mouse models as predictors of human response to therapy.